Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics [0.03%]
Resmetirom的获批：强调NASH治疗中采取全面方法的必要性
Salah Abdalrazak Alshehade
Salah Abdalrazak Alshehade
The recent FDA approval of Rezdiffra (resmetirom), an oral partial agonist of the thyroid hormone receptor-beta (THR-beta), for the treatment of noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced fibrosis, has chall...
Suicide risk is elevated among patients with chronic liver disease and cirrhosis in the United States [0.03%]
美国慢性肝病和肝硬化患者的自杀风险升高
Arian Mansur,Benjamin Grobman,Christine Y Lu
Arian Mansur
Ruifang Hu,Chen Wu,Jinliang Xiao et al.
Ruifang Hu et al.
Massive peritoneal tumoral dissemination after hepatocellular carcinoma percutaneous microwave ablation with intraperitoneal CO2 insufflation [0.03%]
经皮微波消融腹腔内注入二氧化碳治疗原发性肝癌致瘤样种植转移临床病理一例
Romain L&#x;Huillier,Claire Michoud,Jérôme Dumortier et al.
Romain L&#x;Huillier et al.
Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease [0.03%]
预测的英夫利昔α浓度在诱导期间可预示炎症性肠病缓解时间以及持续疾病控制
Severine Vermeire,Marla C Dubinsky,Shervin Rabizadeh et al.
Severine Vermeire et al.
Background: Infliximab (IFX) exposure is established as a predictive factor of pharmacokinetic (PK) origin in inflammatory bowel disease (IBD), and expert consensus is to achieve adequate exposure during induction to achi...
A comprehensive evaluation of serum circCSPP1 as a novel diagnostic and prognostic biomarker for gastric cancer [0.03%]
血清circCSPP1作为胃癌新型诊断和预后生物标志物的全面评估
Hengchuan Shi,Shan Kong
Hengchuan Shi
Purpose: Gastric cancer (GC) has high incidence and mortality due to its low early screening efficiency. Circular RNAs (CircRNAs) are a new class of non-coding RNAs which is closely related to GC. Nevertheless, the clinic...
Pr Francisca Joly
Pr Francisca Joly
Mariana Amaral Raposo,Emília Sousa Oliveira,Andrey Dos Santos et al.
Mariana Amaral Raposo et al.
Cholecystectomy is considered as a safe procedure to treat patients with gallstones. However, epidemiological studies highlighted an association between cholecystectomy and metabolic disorders, such as type 2 diabetes mellitus and metabolic...
Vonoprazan causes symptomatic improvement in non-erosive gastroesophageal reflux disease: A systematic review and meta-analysis [0.03%]
伏诺拉生治疗非糜烂性反流病症状改善的系统评价和.meta.分析
Sanjay Bandyopadhyay,Pooja Verma,Shambo Samrat Samajdar et al.
Sanjay Bandyopadhyay et al.
Objective: To evaluate the efficacy and safety of vonoprazan therapy as compared to conventional proton pump inhibitors (PPIs) or no vonoprazan for non-erosive esophagitis. ...